Videos

Dave Van Meter, president and CEO of Ivantis, updated OIS@ASCRS attendees on the Hydrus Microstent. Ivantis, like Glaukos, is focused on using the Schlemm’s canal…

Russ Trenary, president and CEO of InnFocus, updated OIS@ASCRS on the progress of MicroShunt, which the company says could be the first and only surgical…

Stephen From, CEO of EyeGate Pharma, updated OIS@ASCRS on its acquisition of Jade Therapeutics’ Hyaluronic Acid program. The company paired the HA to create the…

Paul McLean, ClarVista Medical’s CEO, stressed the importance of rotational stability as he extolled the benefits of the company’s Harmoni Modular Intraocular Lens (IOL). The…

Mark Packer, MD, chief medical officer at Cassini, told OIS@ASCRS the cornea measurement company is moving into the diagnosis of dry eye disease. The firm…

Reza Zadno, president and CEO of Avedro, told OIS@ASCRS attendees that the company’s corneal remodeling technology could reach a huge untapped market of people who…

Yari Mitchell, VP, Global Medical Affairs & Business Strategy, delivered a commercial overview and laid out some of the changes AcuFocus has made to its…

Tom Mitro, chief operating officer of Aerie Pharmaceuticals, brought the OIS@ASCRS community up-to-date on the clinical progress for Rhopressa and Roclatan. The company is entering…

Conceived just a few years ago by a team of students at the Stanford Biodesign program, Oculeve’s TrueTear device is positioned to provide desperately needed…